drugset / Trial / NCT02712567
SARC021C: A Continuation Study of TH-CR-406/SARC021
Expanded access
No longer available
Sarcoma Alliance for Research through Collaboration
Threshold Pharmaceuticals · collab
Summary
SARC021C is a nonrandomized, open-label, multicenter, continuation study designed to provide access to TH-302 for patients currently receiving and benefiting from single agent TH-302 therapy as part of the Phase III TH-CR-406/SARC021 study.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Evofosfamide | Other / unclassified | 300 mg/m2 | Intravenous |